Sanofi, a big pharma company, and Genzyme biopharma partners and announced a $1 million gift to support student success programs in the University of Massachusetts Boston’s College of Science and Mathematics.
The announcement of the gift was made at the opening of Sanofi’s new R&D facility at 640 Memorial Drive in Cambridge, which will be focused on cancer research.
Genzyme and Sanofi target their philanthropic giving toward areas of need in communities, with particular focus on science and education, including organizations that foster the next generation of diverse STEM leaders.
The College of Science and Mathematics has developed a highly successful program for advancing student success in STEM majors. This program revamped advising, academic support, and orientation, and developed a learning community program as the centerpiece of this strategy.
Retention in the program is more than 15 points above the college’s preexisting levels, with large increases of students remaining in STEM majors.
The gift from the biopharma partners Sanofi and Genzyme marks the third significant philanthropic gift this year supporting CSM student success programs.
Earlier this year, San Francisco-based software giant Oracle gave $300,000 to support student success efforts in CSM, and Ralph and Janice James pledged $1 million to support student success efforts campus-wide.
For further deal information visit Current Agreements (subscription required)
Read: more on Sanofi company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with Sanofi
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity